The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF a agent treatment in patients with rheumatoid arthritis: A meta-analysis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lv, Qianwen ^a   Yin, Yufeng ^a   Li, Xin ^a   Shan, Guangliang ^b   Wu, Xiangni ^a   Liang, Di ^a   Li, Yongzhe ^a   Zhang, Xuan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG RESPONSE; ETHNICITY; FOLLOW UP; HUMAN; IMMUNE STATUS; META ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS; ODDS RATIO; PEPTIDES, CYCLIC; PUBLICATION BIAS; RHEUMATOID FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897831924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089442     Document Type: Article

References (25)

1. Harris ED (1990) Rheumatoid Arthritis. New England Journal of Medicine 322: 1277-1289.
2. Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, et al. (2009) Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68: 1470-1473.
3. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, et al. (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47: 495-499.
4. Gibbons LJ, Hyrich KL (2009) Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 23: 111-124.
5. Pruijn GJ, Wiik A, van Venrooij WJ (2010) The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Research & Therapy 12: 203.
6. Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anticyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65: 845-851.
7. Vasilopoulos Y, Bagiatis V, Stamatopoulou D, Zisopoulos D, Alexiou I, et al. (2011) Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis. Clinical & Experimental Rheumatology 29: 701-704.
8. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, et al. (2008) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: oneyear clinical outcomes (RECONFIRM-2). Modern Rheumatology 18: 146-152.
9. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, et al. (2009) Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 68: 69-74.
10. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, et al. (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.[Erratum appears in J Rheumatol. 2007 Sep;34(9):1947]. Journal of Rheumatology 34: 1670-1673. (Pubitemid 47267608)
11. Klaasen R, Cantaert T, Wijbrandts CA, Teitsma C, Gerlag DM, et al. (2011) The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology 50: 1487-1493.
12. Cuchacovich M, Catalan D, Wainstein E, Gatica H, Soto L, et al. (2008) Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clinical & Experimental Rheumatology 26: 1067-1073.
13. Canhao H, Rodrigues AM, Mourao AF, Martins F, Santos MJ, et al. (2012) Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 51: 2020-2026.
14. Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, et al. (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. Journal of Rheumatology 33: 497-500. (Pubitemid 43334571)
15. Soto L, Sabugo F, Catalan D, Wurmann P, Cermenatti T, et al. (2011) The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) alpha-308[NON-BREAKING SPACE]G/G promoter polymorphism. Clinical Rheumatology 30: 391-395.
16. Lequerre T, Jouen F, Brazier M, Clayssens S, Klemmer N, et al. (2007) Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology 46: 446-453. (Pubitemid 46344657)
17. Hyrich KL, Watson KD, Silman AJ, Symmons DPM, British Society for Rheumatology Biologics R (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 45: 1558-1565. (Pubitemid 44817065)
18. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, et al. (2007) High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Annals of the Rheumatic Diseases 66: 302-307. (Pubitemid 46579628)
19. Alexandra, Nicaise-Roland P, Hayem G, Palazzo E, Dieude P, et al. (2009) Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with longstanding rheumatoid arthritis. Joint, Bone, Spine: Revue du Rhumatisme 76: 248-253.
20. Hayden JA,̂te' PC, Bombardier C (2006) Evaluation of the Quality of Prognosis Studies in Systematic Reviews. Ann Intern Med 144: 427-437.
21. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, et al. (2008) The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 67: 1139-1144.
22. Bos WH, Bartelds GM, Wolbink GJ, de Koning MHMT, van de Stadt RJ, et al. (2008) Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. Journal of Rheumatology 35: 1972-1977.
23. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, et al. (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Annals of the Rheumatic Diseases. pp. 789-796.
24. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63: 1090-1095. (Pubitemid 39120360)
25. Bongi SM, Manetti R, Melchiorre D, Turchini S, Boccaccini P, et al. (2004) Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37: 495-501. (Pubitemid 40123420)